NEW YORK (GenomeWeb) – Biotage, a Swedish firm specializing in separation technologies, said today it has signed a strategic collaboration with Shandong Yingsheng Biotechnology (Yingsheng) to develop clinical mass spectrometry applications in China.
Terms of the deal call for Biotage to provide systems and consumables from its analytical chemistry portfolio to be sold by Yingsheng under its own brand and together with Yingsheng's other products.
Yingsheng is primarily focused on developing, manufacturing, and selling in vitro diagnostic reagents and medical equipment, and is building a genetic detection platform around metabolomics and genetics.
"This collaboration opens up a market not previously available to Biotage and we believe that Biotage together with Yingsheng have good opportunities to be successful in this market environment," Biotage President and CEO Torben Jörgensen said in a statement, noting that clinical mass spec detection can be used in applications such as vitamin, hormone, and newborn screening.